Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China · Delayed Price · Currency is CNY 11.23
+0.05 (0.45%)
May 6, 2026, 3:04 PM CST
Yifan Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 5,035 | 5,106 | 5,140 | 4,044 | 3,819 | 4,379 |
Other Revenue | 26.61 | 26.61 | 20.29 | 23.61 | 17.51 | 30.45 |
| 5,062 | 5,133 | 5,160 | 4,068 | 3,837 | 4,409 | |
Revenue Growth (YoY) | -1.91% | -0.52% | 26.84% | 6.03% | -12.98% | -18.36% |
Cost of Revenue | 2,725 | 2,757 | 2,745 | 2,139 | 1,983 | 2,594 |
Gross Profit | 2,336 | 2,376 | 2,414 | 1,929 | 1,853 | 1,815 |
Selling, General & Admin | 1,528 | 1,576 | 1,629 | 1,503 | 1,435 | 1,297 |
Research & Development | 282.24 | 291.37 | 291.97 | 312.38 | 190.2 | 196.64 |
Other Operating Expenses | 100.67 | 44.29 | 43.46 | 32.37 | 27.05 | 37.24 |
Operating Expenses | 1,925 | 1,935 | 2,026 | 1,908 | 1,682 | 1,552 |
Operating Income | 411.86 | 441.58 | 388.37 | 20.93 | 171.35 | 262.68 |
Interest Expense | -51.42 | -53.04 | -69.1 | -75.55 | -85.85 | -74.59 |
Interest & Investment Income | 11.55 | 12.06 | 8.12 | 13.13 | 21.39 | 25.3 |
Currency Exchange Gain (Loss) | -1.75 | -1.75 | -2.94 | 14.5 | 50.19 | -17.77 |
Other Non Operating Income (Expenses) | -19.65 | -9.45 | -0.14 | -14.84 | -12.38 | -8.03 |
EBT Excluding Unusual Items | 350.6 | 389.4 | 324.3 | -41.83 | 144.69 | 187.59 |
Impairment of Goodwill | - | - | - | - | - | -11.9 |
Gain (Loss) on Sale of Investments | -24.85 | -27.45 | -14.16 | -15.06 | -17.63 | -4.49 |
Gain (Loss) on Sale of Assets | 12.82 | 12.7 | 30.15 | 2.57 | -0.56 | 14.83 |
Asset Writedown | -32.98 | -30.37 | -73.69 | -872.42 | -102.13 | -26.34 |
Other Unusual Items | 82.29 | 79.43 | 122.06 | 57.71 | 132.37 | 51.1 |
Pretax Income | 387.88 | 423.7 | 388.66 | -869.03 | 156.74 | 210.79 |
Income Tax Expense | 56.95 | 50.25 | 65.04 | 16.62 | 29.65 | -31.42 |
Earnings From Continuing Operations | 330.93 | 373.45 | 323.62 | -885.65 | 127.09 | 242.21 |
Minority Interest in Earnings | 24.75 | 28.57 | 62.35 | 334.58 | 64.13 | 36.18 |
Net Income | 355.69 | 402.02 | 385.97 | -551.07 | 191.22 | 278.4 |
Net Income to Common | 355.69 | 402.02 | 385.97 | -551.07 | 191.22 | 278.4 |
Net Income Growth | -9.50% | 4.16% | - | - | -31.31% | -71.25% |
Shares Outstanding (Basic) | 1,218 | 1,218 | 1,206 | 1,225 | 1,195 | 1,210 |
Shares Outstanding (Diluted) | 1,218 | 1,218 | 1,206 | 1,225 | 1,275 | 1,210 |
Shares Change (YoY) | 1.00% | 1.00% | -1.51% | -3.94% | 5.32% | -1.26% |
EPS (Basic) | 0.29 | 0.33 | 0.32 | -0.45 | 0.16 | 0.23 |
EPS (Diluted) | 0.29 | 0.33 | 0.32 | -0.45 | 0.15 | 0.23 |
EPS Growth | -10.40% | 3.13% | - | - | -34.78% | -70.89% |
Free Cash Flow | -102.9 | -100.87 | 12.57 | -155.5 | -70.21 | -270.51 |
Free Cash Flow Per Share | -0.08 | -0.08 | 0.01 | -0.13 | -0.06 | -0.22 |
Dividend Per Share | 0.100 | 0.100 | 0.200 | - | - | - |
Dividend Growth | -50.00% | -50.00% | - | - | - | - |
Gross Margin | 46.16% | 46.29% | 46.79% | 47.42% | 48.30% | 41.16% |
Operating Margin | 8.14% | 8.60% | 7.53% | 0.52% | 4.47% | 5.96% |
Profit Margin | 7.03% | 7.83% | 7.48% | -13.55% | 4.98% | 6.31% |
Free Cash Flow Margin | -2.03% | -1.97% | 0.24% | -3.82% | -1.83% | -6.13% |
EBITDA | 744.64 | 771.96 | 709.19 | 273.5 | 379.13 | 453.82 |
EBITDA Margin | 14.71% | 15.04% | 13.74% | 6.72% | 9.88% | 10.29% |
D&A For EBITDA | 332.78 | 330.39 | 320.83 | 252.57 | 207.78 | 191.14 |
EBIT | 411.86 | 441.58 | 388.37 | 20.93 | 171.35 | 262.68 |
EBIT Margin | 8.14% | 8.60% | 7.53% | 0.51% | 4.47% | 5.96% |
Effective Tax Rate | 14.68% | 11.86% | 16.73% | - | 18.92% | - |
Revenue as Reported | 5,062 | 5,133 | 5,160 | 4,068 | 3,837 | 4,409 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.